BeiGene Ltd. ADR (BGNE): Price and Financial Metrics

BeiGene Ltd. ADR (BGNE): $142.88

4.88 (-3.30%)

POWR Rating

Component Grades








Add BGNE to Watchlist
Sign Up

Industry: Biotech




#60 of 350

in industry

BGNE Price/Volume Stats

Current price $142.88 52-week high $272.49
Prev. close $147.76 52-week low $132.95
Day low $141.54 Volume 237,900
Day high $145.89 Avg. volume 343,263
50-day MA $171.20 Dividend yield N/A
200-day MA $194.11 Market Cap 13.62B

BGNE Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where BGNE ranks best; there it ranks ahead of 90.74% of US stocks.
  • The strongest trend for BGNE is in Sentiment, which has been heading up over the past 26 weeks.
  • BGNE's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).

BGNE Stock Summary

  • With a market capitalization of $18,992,331,352, BEIGENE LTD has a greater market value than 88.73% of US stocks.
  • BGNE's price/sales ratio is 8.62; that's higher than the P/S ratio of 87.57% of US stocks.
  • As for revenue growth, note that BGNE's revenue has grown 76.39% over the past 12 months; that beats the revenue growth of 94.09% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to BEIGENE LTD, a group of peers worth examining would be LCID, RYTM, TDUP, SAGE, and LUMO.
  • Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to

BGNE Valuation Summary

  • BGNE's price/sales ratio is 8.6; this is 290.91% higher than that of the median Healthcare stock.
  • Over the past 96 months, BGNE's EV/EBIT ratio has gone up 41.8.

Below are key valuation metrics over time for BGNE.

Stock Date P/S P/B P/E EV/EBIT
BGNE 2023-12-29 8.6 5.0 -19.7 -16.7
BGNE 2023-12-28 8.5 5.0 -19.6 -16.6
BGNE 2023-12-27 8.5 5.0 -19.5 -16.5
BGNE 2023-12-26 8.3 4.9 -19.1 -16.2
BGNE 2023-12-22 8.4 4.9 -19.2 -16.2
BGNE 2023-12-21 8.4 4.9 -19.3 -16.3

BGNE Growth Metrics

    Its 4 year price growth rate is now at 330.2%.
  • Its 3 year net income to common stockholders growth rate is now at -159.78%.
  • The year over year cash and equivalents growth rate now stands at 128.56%.
Over the past 49 months, BGNE's revenue has gone up $1,092,081,000.

The table below shows BGNE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1,249.805 -1,686.267 -2,148.932
2022-06-30 1,068.617 -1,620.074 -2,005.231
2022-03-31 877.037 -1,660.381 -1,914.123
2021-12-31 1,176.283 -1,298.723 -1,413.354
2021-09-30 1,062.404 -1,123.218 -1,300.446
2021-06-30 947.044 -973.746 -1,311.815

BGNE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BGNE has a Quality Grade of C, ranking ahead of 25.08% of graded US stocks.
  • BGNE's asset turnover comes in at 0.168 -- ranking 211th of 681 Pharmaceutical Products stocks.
  • AADI, CPIX, and NAVB are the stocks whose asset turnover ratios are most correlated with BGNE.

The table below shows BGNE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.168 0.883 -0.377
2021-03-31 0.165 0.897 -0.358
2020-12-31 0.065 0.771 -0.552
2020-09-30 0.070 0.746 -0.678
2020-06-30 0.078 0.704 -0.890
2020-03-31 0.166 0.826 -0.893

BeiGene Ltd. ADR (BGNE) Company Bio

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019. (Source:Wikipedia)

BGNE Latest News Stream

Event/Time News Detail
Loading, please wait...

BGNE Latest Social Stream

Loading social stream, please wait...

View Full BGNE Social Stream

Latest BGNE News From Around the Web

Below are the latest news stories about BEIGENE LTD that investors may wish to consider to help them evaluate BGNE as an investment opportunity.

12 High Growth International Stocks to Buy

In this article, we discuss the 12 high growth international stocks to buy. If you want to read about some more high growth international stocks, go directly to 5 High Growth International Stocks to Buy. There is general optimism on Wall Street that the Federal Reserve in the United States will be able to achieve […]

Yahoo | December 28, 2023

FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., December 22, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved a label update for BRUKINSA® (zanubrutinib) to include superior progression-free survival (PFS) results from the Phase 3 ALPINE trial comparing BRUKINSA against IMBRUVICA® (ibrutinib) in previously treated patients with relapsed or refractory (R/R) chronic lymphocytic le

Yahoo | December 22, 2023

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

Yahoo | December 21, 2023

BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., December 21, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024 with a presentation at 1:30 pm PT.

Yahoo | December 21, 2023

13 Most Promising Healthcare Stocks According to Analysts

In this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […]

Yahoo | December 19, 2023

Read More 'BGNE' Stories Here

BGNE Price Returns

1-mo -21.27%
3-mo -28.24%
6-mo -27.72%
1-year -42.84%
3-year -61.28%
5-year 10.54%
YTD -20.78%
2023 -18.00%
2022 -18.82%
2021 4.85%
2020 55.88%
2019 18.18%

Continue Researching BGNE

Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:

BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!